Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
复制标题
DOI：
10.1159/000341783
复制
发表时间：
2012-01
影响因子：
2.3
通讯作者：
Zandi PP
中科院分区：
文献类型：
--
作者：
Drye LT;Zandi PP
阿尔茨海默病抗炎预防试验（ADAPT）测试了非甾体抗炎药（NSAID）是否可以预防阿尔茨海默病（AD）。结果为空。我们分析了ADAPT数据，以检查NSAIDs对AD风险的影响是否与既往观察性研究所提示的APOE基因型或年龄有关。ADAPT将2，528名认知功能完好的老年人随机分配到塞来昔布，那普利钠或安慰剂组; 2，388名参与者提供了APOE基因分型的血液样本。采用比例风险回归法，根据入组时的年龄和APOE基因型，评估纳洛芬或塞来昔布与安慰剂相比对AD发病率的影响。治疗组间提供生物样本的受试者比例无差异。在AD风险模型中，NSAID与年龄或APOE基因型之间的双向相互作用检验均无显著性（p > 0.05）。数据不支持NSAID和AD风险之间的关联因年龄或APOE基因型而异的假设。
The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) tested whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent Alzheimer's disease (AD). The results were null. We analyzed ADAPT data to examine if the effects of NSAIDs on AD risk differed depending upon APOE genotype or age as has been suggested by previous observational studies. ADAPT randomized 2,528 cognitively intact older adults to either celecoxib, naproxen sodium or placebo; 2,388 participants provided blood samples for APOE genotyping. Proportional hazards regression was used to estimate the effects of naproxen or celecoxib versus placebo on incident AD by age at enrollment and APOE genotype. The proportion of subjects providing a biological sample did not differ between the treatment groups. In models of AD risk, none of the tests for 2-way interactions between either NSAID and age or APOE genotype were significant (p > 0.05). The data did not support the hypothesis that the association between NSAIDs and AD risk differed by age or APOE genotype.